|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Aura Biosciences, Inc. (AURA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
49,210,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aura Biosciences is a clinical-stage biotechnology company using its targeted oncology platform to develop a potential new standard of care across various cancer indications, with an initial focus on ocular and urologic oncology. Co.'s proprietary platform enables the targeting of a range of solid tumors using Virus-Like Particles that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDC). AU-011, Co.'s VDC candidate, is being developed for the first line treatment of primary choroidal melanoma. In addition, Co. is developing AU-011 for the treatment of non-muscle invasive bladder cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,779,667 |
3,045,667 |
Total Buy Value |
$0 |
$0 |
$15,643,162 |
$30,826,673 |
Total People Bought |
0 |
0 |
2 |
2 |
Total Buy Transactions |
0 |
0 |
7 |
12 |
Total Shares Sold |
0 |
22,462 |
46,782 |
57,290 |
Total Sell Value |
$0 |
$171,662 |
$396,896 |
$527,771 |
Total People Sold |
0 |
2 |
2 |
4 |
Total Sell Transactions |
0 |
2 |
6 |
10 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kilroy Conor |
General Counsel and Secretary |
|
2024-04-02 |
4 |
A |
$0.00 |
$0 |
D/D |
96,000 |
96,000 |
|
- |
|
Plavsic Mark |
Chief Technology Officer |
|
2024-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
128,515 |
|
- |
|
De Los Pinos Elisabet |
See Remarks |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
162,935 |
324,373 |
|
- |
|
Hopkins Janet Jill |
Chief Medical Officer |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
28,515 |
163,515 |
|
- |
|
Feder Julie B |
Chief Financial Officer |
|
2024-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
71,285 |
134,276 |
|
- |
|
Feder Julie B |
Chief Financial Officer |
|
2024-01-23 |
4 |
S |
$7.64 |
$50,521 |
D/D |
(6,609) |
62,991 |
|
- |
|
De Los Pinos Elisabet |
See Remarks |
|
2024-01-23 |
4 |
S |
$7.64 |
$121,141 |
D/D |
(15,853) |
161,438 |
|
- |
|
Goel David E. |
10% Owner |
|
2023-11-09 |
4 |
B |
$9.00 |
$14,040,000 |
I/I |
1,560,000 |
6,922,870 |
1.5 |
- |
|
Johnson David Michael |
|
|
2023-11-08 |
4 |
B |
$7.30 |
$146,000 |
I/I |
20,000 |
75,000 |
0.01 |
- |
|
Johnson David Michael |
|
|
2023-11-08 |
4 |
B |
$7.30 |
$70,087 |
D/D |
9,601 |
135,667 |
0.01 |
- |
|
Johnson David Michael |
|
|
2023-11-07 |
4 |
B |
$7.17 |
$673,980 |
I/I |
94,000 |
65,000 |
0.01 |
- |
|
Johnson David Michael |
|
|
2023-11-07 |
4 |
B |
$7.17 |
$544,920 |
D/D |
76,000 |
126,066 |
0.01 |
- |
|
De Los Pinos Elisabet |
See Remarks |
|
2023-11-06 |
4 |
AS |
$12.03 |
$89,611 |
D/D |
(7,449) |
177,291 |
|
- |
|
De Los Pinos Elisabet |
See Remarks |
|
2023-11-06 |
4 |
OE |
$2.74 |
$10,412 |
D/D |
3,800 |
184,740 |
|
- |
|
Feder Julie B |
Chief Financial Officer |
|
2023-11-06 |
4 |
AS |
$12.07 |
$47,054 |
D/D |
(3,900) |
69,600 |
|
- |
|
Feder Julie B |
Chief Financial Officer |
|
2023-11-06 |
4 |
OE |
$2.74 |
$10,686 |
D/D |
3,900 |
73,500 |
|
- |
|
De Los Pinos Elisabet |
See Remarks |
|
2023-10-30 |
4 |
S |
$6.83 |
$65,478 |
D/D |
(9,586) |
180,940 |
|
- |
|
Feder Julie B |
Chief Financial Officer |
|
2023-10-30 |
4 |
S |
$6.82 |
$23,091 |
D/D |
(3,385) |
69,600 |
|
- |
|
Johnson David Michael |
|
|
2023-10-04 |
4 |
B |
$8.61 |
$56,512 |
D/D |
6,566 |
50,066 |
0.01 |
- |
|
Johnson David Michael |
|
|
2023-10-03 |
4 |
B |
$8.27 |
$111,663 |
D/D |
13,500 |
43,500 |
0.01 |
- |
|
De Rosch Mark |
Chief Operating Officer |
|
2023-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
42,250 |
58,635 |
|
- |
|
Rich Cadmus |
See Remarks |
|
2023-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
34,125 |
58,703 |
|
- |
|
De Los Pinos Elisabet |
See Remarks |
|
2023-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
121,875 |
190,526 |
|
- |
|
Feder Julie B |
Chief Financial Officer |
|
2023-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
48,750 |
72,985 |
|
- |
|
Johnson David Michael |
Director |
|
2023-01-06 |
4 |
B |
$10.50 |
$16,851 |
I/I |
1,604 |
18,000 |
2.1 |
- |
|
45 Records found
|
|
Page 1 of 2 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|